Literature DB >> 18695115

Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy.

Joseph D Benevento1, Rama D Jager, A Gwendolyn Noble, Paul Latkany, William F Mieler, Mari Sautter, Sanford Meyers, Marilyn Mets, Michael A Grassi, Peter Rabiah, Kenneth Boyer, Charles Swisher, Rima McLeod.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18695115      PMCID： PMC2741687          DOI： 10.1001/archopht.126.8.1152

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN： 0003-9950


× No keyword cloud information.
  6 in total

1.  Visual outcome after surgical removal of choroidal neovascularization in pediatric patients.

Authors:  A Uemura; M A Thomas
Journal:  Arch Ophthalmol       Date:  2000-10

2.  Subretinal neovascularization associated with presumed toxoplasmic retinochoroidal scar.

Authors:  F Kayazawa
Journal:  Ann Ophthalmol       Date:  1982-09

3.  Subretinal neovascularisation in ocular toxoplasmosis.

Authors:  A M Cotliar; A H Friedman
Journal:  Br J Ophthalmol       Date:  1982-08       Impact factor: 4.638

4.  The host cell transcription factor hypoxia-inducible factor 1 is required for Toxoplasma gondii growth and survival at physiological oxygen levels.

Authors:  Wade Spear; Denise Chan; Isabelle Coppens; Randall S Johnson; Amato Giaccia; Ira J Blader
Journal:  Cell Microbiol       Date:  2006-02       Impact factor: 3.715

5.  Surgery for subfoveal choroidal neovascularization in toxoplasmic retinochoroiditis.

Authors:  Alfredo Adán; Carlos Mateo; Charlotte Wolley-Dod
Journal:  Am J Ophthalmol       Date:  2003-03       Impact factor: 5.258

6.  Choroidal neovascularization as a late complication of ocular toxoplasmosis.

Authors:  S L Fine; S L Owens; J A Haller; D L Knox; A Patz
Journal:  Am J Ophthalmol       Date:  1981-03       Impact factor: 5.258
  6 in total
  19 in total

1.  Choroidal neovascularization in 36 eyes of children and adolescents.

Authors:  P Rishi; A Gupta; E Rishi; B J Shah
Journal:  Eye (Lond)       Date:  2013-07-26       Impact factor: 3.775

2.  Identification of a sporozoite-specific antigen from Toxoplasma gondii.

Authors:  Dolores Hill; Cathleen Coss; J P Dubey; Kristen Wroblewski; Mari Sautter; Tiffany Hosten; Claudia Muñoz-Zanzi; Ernest Mui; Shawn Withers; Kenneth Boyer; Gretchen Hermes; Jessica Coyne; Frank Jagdis; Andrew Burnett; Patrick McLeod; Holmes Morton; Donna Robinson; Rima McLeod
Journal:  J Parasitol       Date:  2011-03-03       Impact factor: 1.276

3.  Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America.

Authors:  Kenneth Boyer; Dolores Hill; Ernest Mui; Kristen Wroblewski; Theodore Karrison; J P Dubey; Mari Sautter; A Gwendolyn Noble; Shawn Withers; Charles Swisher; Peter Heydemann; Tiffany Hosten; Jane Babiarz; Daniel Lee; Paul Meier; Rima McLeod
Journal:  Clin Infect Dis       Date:  2011-10-21       Impact factor: 9.079

4.  Prematurity and severity are associated with Toxoplasma gondii alleles (NCCCTS, 1981-2009).

Authors:  Rima McLeod; Kenneth M Boyer; Daniel Lee; Ernest Mui; Kristen Wroblewski; Theodore Karrison; A Gwendolyn Noble; Shawn Withers; Charles N Swisher; Peter T Heydemann; Mari Sautter; Jane Babiarz; Peter Rabiah; Paul Meier; Michael E Grigg
Journal:  Clin Infect Dis       Date:  2012-04-11       Impact factor: 9.079

5.  Response of Pediatric Choroidal Neovascularization to Anti-Vascular Endothelial Growth Factor.

Authors:  Sunil Ruparelia; Aishwarya Sundaram; Mishari Dahrab; Chris Symonds; Alan Cruess
Journal:  Cureus       Date:  2021-12-06

Review 6.  Why prevent, diagnose and treat congenital toxoplasmosis?

Authors:  Rima McLeod; Francois Kieffer; Mari Sautter; Tiffany Hosten; Herve Pelloux
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-03       Impact factor: 2.743

7.  Intravitreal ranibizumab for choroidal neovascularization related to traumatic Bruch's membrane rupture.

Authors:  Feng Liang; Nathalie Puche; Gisèle Soubrane; Eric H Souied
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-26       Impact factor: 3.117

8.  Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to ocular toxoplasmosis.

Authors:  Nikunj J Shah; Urmi N Shah
Journal:  Indian J Ophthalmol       Date:  2011 Jul-Aug       Impact factor: 1.848

9.  Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis.

Authors:  Sarra E Jamieson; Lee-Anne de Roubaix; Mario Cortina-Borja; Hooi Kuan Tan; Ernest J Mui; Heather J Cordell; Michael J Kirisits; E Nancy Miller; Christopher S Peacock; Aubrey C Hargrave; Jessica J Coyne; Kenneth Boyer; Marie-Hélène Bessieres; Wilma Buffolano; Nicole Ferret; Jacqueline Franck; François Kieffer; Paul Meier; Dorota E Nowakowska; Malgorzata Paul; François Peyron; Babill Stray-Pedersen; Andrea-Romana Prusa; Philippe Thulliez; Martine Wallon; Eskild Petersen; Rima McLeod; Ruth E Gilbert; Jenefer M Blackwell
Journal:  PLoS One       Date:  2008-06-04       Impact factor: 3.240

10.  Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization.

Authors:  Ahmad M Mansour; Friederike Mackensen; Padmamalini Mahendradas; Moncef Khairallah; Timothy Yy Lai; Ziad Bashshur
Journal:  Clin Ophthalmol       Date:  2012-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.